CRH Medical Corp. | StockChase
80
CRH Medical Corp. (CRH-T)

Last Price Recorded: $2.4400 on 2017-11-23

ON STOCKCHASE SINCE Jul 2009

biotechnology/pharmaceutical

CRH Medical Corp.


Signal Opinion Expert
     

2017-11-14

DON'T BUY
CRH Medical Corp. (CRH-T)

Thinks management got caught off guard with the Medicare/Medicaid changes. Listening to the calls, he didn’t have a lot of confidence. Their business model is a bit broken now. With the share price and valuation so low, they are not getting as much bang for their buck now. Heading into the tax loss season, this is probably going to be one of the big targets. He would sit on the sidelines, at least until the new year.

biotechnology/pharmaceutical
Ryan Modesto

Managing Partner, 5i Research

Price: $1.920
Owned: Unknown

2017-11-13

COMMENT
CRH Medical Corp. (CRH-T)

They are in the US mainly and partner with anesthesiologists, for gut surgeries.  There is a whole system in the US as to who can treat whom and what they will pay.  These guys have been hit because of lack of organic growth and the concern is whether the reduced amount the Medicaid is willing to pay will impact margins going forward.  He thinks it is overdone.

biotechnology/pharmaceutical
Brendan Caldwell

President, Caldwell Securities

Price: $2.080
Owned: Unknown

2017-11-08

PAST TOP PICK
CRH Medical Corp. (CRH-T)

(A Top Pick Nov 16/16. Down 71%.) A few things happened. Have had 2 reimbursement cuts. Hasn’t affecting earnings yet, but it will. It’s been an acquisition story and they’ve been buying anaesthesiology clinics using their stock as currency. That becomes difficult now because of the low stock price.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investment Management Inc.

Price: $2.180
Owned: No

2017-10-19

DON'T BUY
CRH Medical Corp. (CRH-T)

It has not done anything at all for him and is on a short leash.  It is drifting back now.  He would be concerned about tax loss selling soon.  There is value there but don’t start a position.

biotechnology/pharmaceutical
Peter Hodson

CEO & Head of Research, 5i Research Inc.

Price: $2.940
Owned: Yes

2017-10-04

TOP PICK
CRH Medical Corp. (CRH-T)

Has been looking at this for over 2 years, and met management repeatedly. Was aware of the Short attack circulating this summer, which had some pretty interesting important points to make. When a share price goes from $12 to around $3, his view is that it was fully priced in and there was a big overreaction by the street. They are exclusively based in the US, and have a medical product that is used by gastroenterologists in the clinics, kind of a Trojan horse for them because they have the clinics that are using the medical product, so have a relationship with them. With a number of the clinics, they have effectively bought 50% of the clinic, which allows them to provide the anaesthesia services on behalf of the doctors who work there. A pristine balance sheet. (Analysts’ price target is $5.)

biotechnology/pharmaceutical
Jerome Hass

Portfolio Manager, Lightwater Partners

Price: $3.260
Owned: Yes

2017-09-28

SELL
CRH Medical Corp. (CRH-T)

He exited this story.  He was a big bull.  It came back for stock specific stories.  Multiple compression resulted from short reports. 

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $2.890
Owned: No

2017-09-18

HOLD
CRH Medical Corp. (CRH-T)

Had a tremendous run up to about $12, but got completely blindsided, and it pulled back heavily. Got stopped out around mid-$6. Thinks they are going to be okay long-term. There were some issues with insider selling at higher levels. If you own, continue to hold as it looks like it has bottomed.

biotechnology/pharmaceutical
Jason Del Vicario

Portfolio Manager, HollisWealth

Price: $3.190
Owned: No

2017-08-23

DON'T BUY
CRH Medical Corp. (CRH-T)

It had an amazing run this year.  It was a target of some short sellers, and then they missed on some earnings reports.  It is the worst for price momentum.  It is actually okay on valuation.  It has a decent balance sheet.  It is volatile and has poor price momentum.

biotechnology/pharmaceutical
Jason Mann

CIO & Co-Founder, Edgehill Patners

Price: $3.050
Owned: Unknown

2017-08-22

WEAK BUY
CRH Medical Corp. (CRH-T)

It fell apart and is now working itself back.  It got destroyed by credibility, short sellers came along and the stock has readjusted.  He thinks the worst is over.  It has earnings potential.

biotechnology/pharmaceutical
Peter Hodson

CEO & Head of Research, 5i Research Inc.

Price: $3.120
Owned: Yes

2017-08-15

COMMENT
CRH Medical Corp. (CRH-T)

A stock that is extremely popular with medical analysts. There has been a bit of a foul-up in performance and the stock has joined the Bear market. He doesn’t get the sense that it is as good as a lot of analysts seem to believe. You also have the setback of the Obama-care saga in the US.

biotechnology/pharmaceutical
Michael Smedley

Exec VP & Chief Investment Officer, Morgan Meighan & Associates

Price: $3.180
Owned: No

2017-08-02

COMMENT
CRH Medical Corp. (CRH-T)

Provides anaesthesia services for gastro-intestinal procedures. They operate in the US, and Medicare and Medicaid are evaluating what people can bill for services. The company has said that the net impact will probably result in an 8% decline in revenue and a 16%-18% decline in EBITDA. When the news broke, the shares dropped about 50%-65%, so it is getting to a time where it has probably been a little oversold. This is going to be higher risk, so you need to be able to withstand 5% moves on any given day. They just did another acquisition and there is a hint that they will be doing many more.

biotechnology/pharmaceutical
Ryan Modesto

Managing Partner, 5i Research

Price: $4.600
Owned: Unknown

2017-07-26

COMMENT
CRH Medical Corp. (CRH-T)

This has been hit extremely hard. It trades to a pretty significant multiple and probably got ahead of itself. On the news and speculation that some kind of reimbursement was going to come, the stock sold down. The code changes are not being reimbursed to the same degree. In the past, they’ve been able to use their currency to a certain degree to make acquisitions. They have just secured a bigger line, so it looks like they’ve shored up their business fairly well. Fairly good cash flow. The reimbursement is going to hurt them, and then the private pay insurance, the majority of their business, will end up coming down over time as well. They are going to have to replace the lost revenue with increased business, either organically or by acquisition.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investment Management Inc.

Price: $4.260
Owned: Unknown

2017-07-24

COMMENT
CRH Medical Corp. (CRH-T)

News items make it difficult for anyone to analyze.  They have one of the best returns of capital.  The rules have changed.  Probably it is okay.  Usually the rule changes sound more threatening than they really are.

biotechnology/pharmaceutical
Matt Kacur

President, FSA Financial Science and Art

Price: $4.500
Owned: Unknown

2017-07-17

WATCH
CRH Medical Corp. (CRH-T)

He has no price target.  It is another great Canadian healthcare stock that got hammered a short while ago.  The reason for the most recent decline is that Central Medical Services has changed how they code some services.  This company should eventually be at higher prices, but he wants to see the dust settle.

biotechnology/pharmaceutical
Brendan Caldwell

President, Caldwell Securities

Price: $4.670
Owned: No

2017-07-13

HOLD
CRH Medical Corp. (CRH-T)

An outsourcer in medical clinics where they take a 50% stake in the business. Registered nurses are being paid as full medical doctors. Their profitability could be hit when they are re-rated. The argument goes on.  He thinks the short thesis is a little overplayed. 

biotechnology/pharmaceutical
Jerome Hass

Portfolio Manager, Lightwater Partners

Price: $6.620
Owned: Unknown

Showing 1 to 15 of 80 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.